Patient Representativeness With Virtual Enrollment in the PRO-HF Trial.

"Disclosures Dr Sandhu is supported by the National Heart, Lung, and Blood Institute (1K23HL151672‐03) and has consulting relationships with Lexicon Pharmaceuticals and Reprieve Cardiovascular. Dr Rodriguez reports consulting relationships with Healthpals, Novartis, NovoNordisk, and AstraZeneca outside the submitted work. Dr Kalwani reports stock options from Gordy Health and funding from the US Agency for Healthcare Research and Quality (T32 HS026128). Drs Azizi, Hernandez, and Wang were funded by American Heart Association Strategically Focused Research Network. The remaining authors have no disclosures to report."

"Sources of Funding The PRO‐HF (Patient‐Reported Outcomes in Heart Failure Clinic) trial is supported by the National Heart, Lung, and Blood Institute (1K23HL151672‐01) and Stanford institutional funding. The data collection is supported by the National Institutes of Health (UL1 TR001085)."